GlassScriptPhysician profile
Marnie Obrien
NPI 1679516496
$3,937.22
in general payments reported to CMS, 2019-2025
24 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $186 · 2021: $413 · 2022: $729 · 2023: $800 · 2024: $688 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,679.96 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $361.88 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $258.89 | 2020-2025 | Cequa |
| Dompe US, INC. | $172.44 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $172.01 | 2019-2022 | |
| Amgen INC. | $145.75 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $138.50 | 2024-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Allergan, INC. | $126.63 | 2020 | |
| Oyster Point Pharma, INC. | $123.38 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $119.84 | 2024-2025 | Idosetr, Idose |
| Bausch & Lomb Americas INC. | $110.68 | 2022-2025 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $107.64 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $91.06 | 2021 | |
| Ocular Therapeutix, INC. | $67.30 | 2019-2023 | Dextenza |
| Harrow Eye, LLC | $52.83 | 2024-2025 | Vevye, Iheezo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $40.71 | 2019-2025 | Lipiflow System Activator (Disposable) |
| Alexion Pharmaceuticals, INC. | $32.74 | 2025 | Ultomiris |
| Shire North American Group INC | $24.39 | 2019 | |
| Rxsight INC | $24.05 | 2022 | |
| Sight Sciences, INC. | $20.53 | 2021 | |
| Biotissue Holdings INC. | $17.79 | 2025 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Horizon Therapeutics Plc | $15.93 | 2023 | Tepezza |
| New World Medical,INC. | $15.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marnie Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.